Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Viemed Healthcare (VMD) Amortization of Deferred Charges (2024 - 2026)

Viemed Healthcare filings provide 2 years of Amortization of Deferred Charges readings, the most recent being $107000.0 for Q4 2025.

On a quarterly basis, Amortization of Deferred Charges rose 105.77% to $107000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $228000.0, a 21.93% increase, with the full-year FY2025 number at $228000.0, up 21.93% from a year prior.
Amortization of Deferred Charges hit $107000.0 in Q4 2025 for Viemed Healthcare, up from $57000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $107000.0 in Q4 2025 to a low of $29000.0 in Q2 2025.